Assessment of drug incorporation and release from a novel coronary stent coating

Craig Martin McKittrick, Simon Dixon, Christopher McCormick

Research output: Contribution to conferencePosterpeer-review

15 Downloads (Pure)


The introduction of drug eluting stents (DES) for the treatment of coronary heart disease has significantly reduced in-stent restenosis, however the use of cytostatic agents causes delayed re-endothelialisation of the target vessel. Here we describe the drug release profiles for rapamycin incorporated into a novel acrylic-based polymer designed to promote vascular re-endothelialisation. Understanding drug release from the surface of DES is integral to the stent development process. It is useful for testing the reliability and reproducibility of coatings and for providing insight into mechanisms of drug release.
Original languageEnglish
Publication statusPublished - 30 Aug 2015
Event27th European Conference on Biomaterials - ICE Krakow Congress Centre, Krakow, Poland
Duration: 30 Aug 20153 Sep 2015


Conference27th European Conference on Biomaterials
Abbreviated titleESB 2015


  • drug delivery
  • drug release
  • coronary stent coating
  • drug eluting stents
  • DES


Dive into the research topics of 'Assessment of drug incorporation and release from a novel coronary stent coating'. Together they form a unique fingerprint.

Cite this